Currently, other different combinations, including magrolimab, are under investigation in MDS/AML: magrolimab + anti-PD-L1 atezolizumab (NCT03922477), magrolimab + AZA + venetoclax (NCT0443691), magrolimab + daratumumab, magrolimab + pomalidomide and dexamethasone, magrolimab + bortezomid and dexamethasone (NCT04892446). This evidence concerns the gene CD274 and acute myeloid leukemia.